Differential diagnosis of parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics
Ended Project Grant Awarded Last action
- Award ID
- R44NS124473
- Recipient
-
Amydis, Inc. UEI LCXNBB1KM9K9
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,032,937
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Funding
-
- $5,955,364.00 Federal
- $2,077,573.00 Non-federal
- Funding agency
- National Institute on Aging National Institutes of Health, Department of Health and Human Services
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Parkinson's disease (PD) is the second most common neurodegenerative disease after alzheimer's disease, and a major cause of disability in individuals over 65 years of age. PD belongs to a spectrum of diseases termed the "synucleinopathies", defined by the progressive aggregation of insoluble fibrillary a-synuclein, and includes other disorders such as multiple system atrophy and lewy body dementia. Currently, there are no objective tests that can be used to definitively diagnose PD. In addition, differential diagnosis of synucleinopathies is very challenging and relies heavily on a physician's clinical evaluation. A critical goal in the field is to reliably identify synucleinopathies at early, asymptomatic stages of the disease, to allow the best chance for correct disease modifying or preventative treatments to be effective. This proposal aims to develop a small molecule fluorescent retinal contrast agent as a novel diagnostic for PD and other related synucleinopathies.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $900,109 | $0 | |
| Amendment | $900,109 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $2,077,573 | $0 | |
| Original award | $2,077,573 | $2,077,573 |
Quick answers
Who received award R44NS124473?
R44NS124473 was awarded to Amydis, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 23, 2021.
How much is award R44NS124473 worth?
$8,032,937 has been obligated on R44NS124473: $5,955,364 in federal funding and $2,077,573 in non-federal funding.
Which agency awarded R44NS124473?
National Institute of Neurological Disorders and Stroke (National Institutes of Health) awarded R44NS124473, with funding from National Institute on Aging (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award